Gamida Cell (GMDAQ) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Document Information Line Items
Entity Registrant Name	GAMIDA CELL LTD.
Trading Symbol	GMDA
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		74,380,810
Amendment Flag	false
Entity Central Index Key	0001600847
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38716
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	116 Huntington Avenue
Entity Address, Address Line Two	7th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02116
City Area Code	(617)
Local Phone Number	892-9080
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022		Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 55,071		$ 55,892
Marketable securities	6,224		40,034
Prepaid expenses and other current assets	1,408		2,688
Total current assets	62,703		98,614
NON-CURRENT ASSETS:
Restricted deposits	3,556		3,961
Property, plant and equipment, net	39,940		35,180
Operating lease right-of-use assets	5,459		7,236
Severance pay fund	1,595		2,148
Other long-term assets	1,059		1,647
Total non-current assets	51,609		50,172
Total assets	114,312		148,786
CURRENT LIABILITIES:
Trade payables	1,916		8,272
Employees and payroll accruals	5,689		4,957
Operating lease liabilities	1,880		2,699
Accrued interest of convertible senior notes	551		1,640
Accrued expenses and other current liabilities	12,677		7,865
Total current liabilities	22,713		25,433
NON-CURRENT LIABILITIES:
Convertible senior notes, net	71,999		71,417
Accrued severance pay	1,865		2,396
Long-term operating lease liabilities	4,174		5,603
Total non-current liabilities	78,038		79,416
CONTINGENT LIABILITIES AND COMMITMENTS
Share capital -
Ordinary shares of NIS 0.01 par value - Authorized: 150,000,000 shares at September 30, 2022 (unaudited) and December 31, 2021; Issued 74,466,580 and 59,970,389 at September 30, 2022 (unaudited) and December 31, 2021 respectively; Outstanding: 74,380,810 and 59,970,389 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively	210		169
Treasury ordinary shares of NIS 0.01 par value - 85,770 and 0 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively		[1]
Additional paid-in capital	407,387		381,225
Accumulated deficit	(394,036)		(337,457)
Total shareholders’ equity	13,561		43,937
Total liabilities and shareholders’ equity	$ 114,312		$ 148,786
[1]Represents an amount lower than $1.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)	Sep. 30, 2022 ₪ / shares shares	Sep. 30, 2022 $ / shares shares	Dec. 31, 2021 ₪ / shares shares	Dec. 31, 2021 $ / shares shares
Statement of Financial Position [Abstract]
Ordinary shares par value (in New Shekels per share) | ₪ / shares	₪ 0.01		₪ 0.01
Ordinary shares authorized	150,000,000	150,000,000	150,000,000	150,000,000
Ordinary shares Issued	74,466,580	74,466,580	59,970,389	59,970,389
Ordinary shares outstanding	74,380,810	74,380,810	59,970,389	59,970,389
Treasury ordinary shares par value (in Dollars per share) | $ / shares		$ 0.01		$ 0.01
Treasury ordinary shares	85,770	85,770	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Research and development expenses, net	$ 9,864	$ 11,725	$ 31,732	$ 36,435
Commercial expenses	2,760	5,755	9,832	14,974
General and administrative expenses	4,437	5,001	12,866	12,388
Total operating loss	17,061	22,481	54,430	63,797
Financial expenses, net	741	692	2,149	2,119
Loss	$ 17,802	$ 23,173	$ 56,579	$ 65,916
Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)	$ 0.29	$ 0.39	$ 0.95	$ 1.11
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)	60,440,765	59,281,243	59,821,655	59,219,757

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)	$ 0.29	$ 0.39	$ 0.95	$ 1.11
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)	60,440,765	59,281,243	59,821,655	59,219,757

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands		Ordinary shares		Treasury shares		Additional paid-in capital		Accumulated deficit		Total
Balance at Dec. 31, 2020		$ 166				$ 376,369		$ (247,664)		$ 128,871
Balance (in Shares) at Dec. 31, 2020		59,000,153
Grant of restricted shares		$ 1				(1)
Grant of restricted shares (in Shares)		220,034
Exercise of options		$ 1				565				566
Exercise of options (in Shares)		298,693
Share-based compensation						3,122				3,122
Loss								(65,916)		(65,916)
Balance at Sep. 30, 2021		$ 168				380,055		(313,580)		66,643
Balance (in Shares) at Sep. 30, 2021		59,518,880
Balance at Jun. 30, 2021		$ 167				378,949		(290,407)		88,709
Balance (in Shares) at Jun. 30, 2021		59,427,996
Grant of restricted shares		$ 1				(1)
Grant of restricted shares (in Shares)		63,550
Exercise of options			[1]			10				10
Exercise of options (in Shares)		27,334
Share-based compensation						1,097				1,097
Loss								(23,173)		(23,173)
Balance at Sep. 30, 2021		$ 168				380,055		(313,580)		66,643
Balance (in Shares) at Sep. 30, 2021		59,518,880
Balance at Dec. 31, 2021		$ 169				381,225		(337,457)		43,937
Balance (in Shares) at Dec. 31, 2021		59,970,389
Grant of restricted shares			[1]				[1]				[1]
Grant of restricted shares (in Shares)		3,600
Treasury shares							[1]		[1]		[1]
Treasury shares (in Shares)		(85,770)
Exercise of options			[1]			76				76
Exercise of options (in Shares)		47,426
Issuance of ordinary shares, net of issuance expenses	[2]	$ 41				22,257				22,298
Issuance of ordinary shares, net of issuance expenses (in Shares)	[2]	14,445,165
Share-based compensation						3,829				3,829
Loss								(56,579)		(56,579)
Balance at Sep. 30, 2022		$ 210			[1]	407,387		(394,036)		13,561
Balance (in Shares) at Sep. 30, 2022		74,380,810
Balance at Jun. 30, 2022		$ 169			[1]	383,915		(376,234)		7,850
Balance (in Shares) at Jun. 30, 2022		59,977,188
Treasury shares					[1]		[1]				[1]
Treasury shares (in Shares)		(3,085)
Exercise of options
Issuance of ordinary shares, net of issuance expenses	[3]	$ 41				22,173				22,214
Issuance of ordinary shares, net of issuance expenses (in Shares)	[3]	14,406,707
Share-based compensation						1,299				1,299
Loss								(17,802)		(17,802)
Balance at Sep. 30, 2022		$ 210			[1]	$ 407,387		$ (394,036)		$ 13,561
Balance (in Shares) at Sep. 30, 2022		74,380,810
[1]Represents an amount lower than $1.[2]Issuance costs of $2,081 relating to the follow-on offering and ATM.[3]Issuance costs of approximately $2,079 million relating to the follow-on offering and ATM.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Loss	$ (56,579)	$ (65,916)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation of property, plant and equipment	391	317
Financing expense (income), net	(2,461)	89
Share-based compensation	3,829	3,122
Amortization of debt discount and issuance costs	582	453
Operating lease right-of-use assets	1,922	1,542
Operating lease liabilities	(2,395)	(1,764)
Accrued severance pay, net	23
Increase in prepaid expenses and other assets	1,719	558
Increase (decrease) in trade payables	(6,355)	1,533
Increase (decrease) in accrued expenses and current liabilities	5,079	(1,361)
Net cash used in operating activities	(54,245)	(61,427)
Cash flows from investing activities:
Purchase of property, plant and equipment	(2,865)	(9,577)
Purchase of marketable securities	(4,557)	(97,808)
Proceeds from maturity of marketable securities	37,972	56,717
Proceeds (investments) from restricted deposits	500	(5,803)
Net cash provided by (used in) investing activities	31,050	(56,471)
Cash flows from financing activities:
Proceeds from exercise of options	76	566
Proceeds from share issuance, net	22,298
Proceeds from issuance of convertible senior notes, net		70,777
Net cash provided by financing activities	22,374	71,343
Decrease in cash and cash equivalents	(821)	(46,555)
Cash and cash equivalents at beginning of period	55,892	127,170
Cash and cash equivalents at end of period	55,071	80,615
Significant non-cash transactions:
Purchase of property, plant and equipment on credit	281	1,561
Supplemental disclosures of cash flow information:
Cash paid for interest	$ (4,406)	$ (2,191)

General

General	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
GENERAL	NOTE 1:- GENERAL a. Gamida Cell Ltd. (the “Company”), founded in 1998, is an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases. The Company harnesses its cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. b. The Company has leveraged its NAM platform, or nicotinamide cell expansion technology platform, to develop a pipeline of product candidates designed to address the limitations of other cell therapies. The Company’s proprietary technology allows for the proliferation and enhancement of donor cells, which allows for maintenance of the cells’ functional therapeutic characteristics, providing a potential treatment alternative for patients. The lead product candidate, omidubicel, is an advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant (BMT). In May 2020, the Company reported that omidubicel met its primary endpoint in an international, randomized, multi-center Phase 3 clinical study in 125 patients with high-risk hematologic malignancies undergoing bone marrow transplant and who had no available matched donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT with a graft derived from bone marrow or peripheral blood cells of a matched donor is currently the standard of care treatment for many of these patients, but there is a significant unmet need for patients who cannot find a fully matched donor. In October 2021, the complete results from the Company’s pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published in the peer-reviewed medical journal Blood. The trial achieved its primary endpoint of time to neutrophil engraftment as well as all three of the prespecified secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following transplant, and the number of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints demonstrated statistical significance in an intent-to-treat analysis. Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and has received orphan drug designation in the U.S. and in Europe. In June 2022, the Company announced completion of the rolling Biologics License Application (BLA) submission to the FDA for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. In August 2022, the Company announced the FDA had accepted for filing the Company’s BLA for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant (HSCT). The FDA granted Priority Review for the BLA and has set a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2023. In addition to omidubicel, the Company is developing GDA-201, an investigational natural killer (NK) cell-based cancer immunotherapy that is intended to be used in combination with standard-of-care therapeutic antibodies, as well as other product candidates in the Company’s NK cell pipeline. NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not requiring genetic matching, potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain antibodies. GDA-201 is currently in an investigator-sponsored Phase 1/2 study for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). Data from the 35 patients in the Phase 1/2 study demonstrated that GDA-201 was clinically active and generally well tolerated. Among the 19 patients with NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate of 68%. At the December 2021 Annual Meeting of America Society of Hematology, the Company reported two-year follow-up data from this clinical trial on outcomes and cytokine biomarkers associated with survival. The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at two years of 78% (95% CI, 51%-91%) and a safety profile similar to that reported previously. On April 26, 2022, the Company announced that the FDA cleared its investigational new drug (IND) application and removed the clinical hold for a cryopreserved formulation of GDA-201. In June, the Company announced the activation of the initial clinical sites to screen and enroll patients in the company-sponsored Phase 1/2 study evaluating a cryopreserved formulation of GDA-201, a readily available cell therapy candidate for the treatment of follicular and diffuse large B cell lymphomas. In September 2022 the Company closed a public offering of its ordinary shares and raised an additional $18.1 million, net of issuance costs. The Company currently intends to use the net proceeds of the offering, together with its existing cash and cash equivalents and trading financial assets to fund: (i) commercial readiness activities to support potential launch of Omidubicel, if approved; (ii) continued clinical development of NK product candidates, including GDA-201; and (iii) general corporate purposes, including general and administrative expenses and working capital. c. Basis of presentation of the financial statements: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K as of December 31, 2021 filed with the SEC on March 24, 2022. The interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB), as permitted in the United States based on the Company’s qualification as a “foreign private issuer” under the rules and regulations of the SEC. In connection with the loss of the Company’s status as a foreign private issuer effective on January 1, 2022, the Company, as a domestic filer, prepared its consolidated financial statements in accordance with U.S. GAAP. d. The Company continues to devote substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of September 30, 2022 was $394.036 and negative cash flows from operating activities during the nine-month period ended September 30, 2022 was $54.246. The Company’s management plans to seek additional financing as required to fund its operations until achieving positive cash flows. However, there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts required. e. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company were unable to continue as a going concern. f. The Company has a wholly owned U.S. subsidiary, Gamida Cell Inc. (the “Subsidiary”), which was incorporated in 2000, under the laws of the State of Delaware. The Company has one operating segment and reporting unit.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates: The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates. b. Convertible senior notes: The Company accounts for its convertible senior notes in accordance with ASC 470-20 “Debt with Conversion and Other Options.” The Company early adopted ASU 2020-06 using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40. c. Basic and diluted net loss per share: The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis. These participating securities do not contractually require the holders of such shares to participate in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities. The Company’s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive ordinary shares are anti-dilutive.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
LEASES	NOTE 3:- LEASES The Company entered into operating leases primarily for its production plant, and its laboratories and offices. The leases have remaining lease terms of up to six years, and the Company does not assume renewals in its determination of the lease term unless the renewals are considered as reasonably certain at lease commencement. The components of operating lease costs were as follows: Nine months ended 2022 2021 (unaudited) (unaudited) Operating lease costs $ 2,093 $ 1,754 Short-term lease costs 92 84 Total lease costs $ 2,185 $ 1,838 Supplemental balance sheet information related to operating leases is as follows: Nine months (unaudited) Weighted average remaining lease term (in years) 3.88 Weighted average discount rate 2.61 % Maturities of lease liabilities were as follows: As of 2022 $ 654 2023 1,589 2024 1,595 2025 1,195 2026 700 Thereafter 538 Total undiscounted lease payments 6,271 Less: Imputed interest (217 ) Present value of lease liabilities $ 6,054

Convertible Senior Notes, Net

Convertible Senior Notes, Net	9 Months Ended
	Sep. 30, 2022
Convertible Senior Notes, Net [Abstract]
CONVERTIBLE SENIOR NOTES, NET	NOTE 4:- CONVERTIBLE SENIOR NOTES, NET On February 16, 2021, the Subsidiary issued convertible senior notes (the “Convertible Notes”) due in 2026, in the aggregate principal amount of $75 million, pursuant to an Indenture between the Company, the Subsidiary, and Wilmington Savings Fund Society, FSB, dated February 16, 2021 (the “Indenture”). The Convertible Notes bear interest payable semiannually in arrears, at a rate of 5.875% per year. The Convertible Notes will mature on February 15, 2026, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to the provisions of the Indenture, the holders of the Convertible Notes have the right, prior to the close of business on the second scheduled trading day immediately preceding February 15, 2026, to convert any Convertible Notes or portion thereof that is $1,000 or an integral multiple thereof, into the Company’s ordinary shares at an initial conversion rate of 56.3063 shares per $1,000 principal amount of Convertible Notes (equivalent to an exchange price of $17.76 per share). The conversion rate is subject to adjustment in specified events. Upon the occurrence of a fundamental change (as defined in the Indenture), holders of the Convertible Notes may require the Company to repurchase for cash all or a portion of their Convertible Notes, in multiples of $1,000 principal amount, at a repurchase price equal to 100% of the principal amount of the Convertible Notes, plus any accrued and unpaid interest, if any, to, but excluding, interest accrued after the date of such repurchase notice. If certain fundamental changes referred to as make-whole fundamental changes occur, the conversion rate for the Convertible Notes may be increased. Subject to the provisions of the Indenture, the Subsidiary may redeem for cash all or a portion of the Convertible Notes for cash, at its option, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest on the notes to be redeemed, if the last reported closing price of the Company’s ordinary shares has been at least 130% of the exchange price then in effect for at least 20 trading days during any 30 consecutive trading day period, and in the event of certain tax law changes. The Convertible Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40. As of Liability component: Principal amount $ 75,000 Issuance costs (4,223 ) Net of issuance costs 70,777 Amortized issuance costs 1,222 Net carrying amount $ 71,999 The total issuance costs of the Convertible Notes amounted to $4,223 and are amortized to interest expenses at an annual effective interest rate of 7.37%, over the term of the Convertible Notes.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 5:- FAIR VALUE MEASUREMENTS The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and marketable securities, are stated at their carrying value, which approximates their fair value due to the short time to the expected receipt or payment. The following table presents information about our financial instruments that are measured at the fair value as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 Level 1 Level 2 Total Level 1 Level 2 Total Financial assets: Money market funds included in cash and cash equivalents $ 49,395 $ - $ 49,935 $ 51,021 $ - $ 51,021 Marketable securities: Corporate debentures - 2,841 2,841 - 19,605 19,605 Government debentures - 3,383 3,383 - 20,429 20,429 Total assets measured at fair value $ 49,395 $ 6,224 $ 55,619 $ 51,021 $ 40,034 $ 91,055 We classify our cash equivalents and marketable securities within Level 1 or Level 2 because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	9 Months Ended
	Sep. 30, 2022
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	NOTE 6:- CONTINGENT LIABILITIES AND COMMITMENTS a. Legal proceedings: From time to time, the Company or its subsidiary may be involved in legal proceedings and/or litigation arising in the ordinary course of business. While the outcome of these matters cannot be predicted with certainty, the Company does not believe it will have a material effect on its consolidated financial position, results of operations, or cash flows. b. Bank guarantees: As of September 30, 2022, the Company obtained bank guarantees in the amount of $2,929, primarily in connection with an Investment Center grant of up to $2,786 expected to be received in 2022 which requires a bank guarantee in order to ensure the fulfillment of the grant terms. c. Governments grants: The Company has received grants from the IIA to finance its research and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $36.8 million through September 30, 2022, of which $34.2 million is royalty-bearing grants and $2.6 million is non-royalty-bearing grants. In return, the Company is committed to pay IIA royalties at a rate of 3-3.5% of future sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through September 30, 2022, no royalties have been paid or accrued. The Company’s contingent royalty liability to the IIA at September 30, 2022, including grants received by the Company and the associated LIBOR interest on all such grants totaled to $42.2 million.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2022
Shareholders' Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 7:- SHAREHOLDERS’ EQUITY a. Ordinary shares: Subject to the Company’s amended and restated Articles of Association, the holders of the Company’s ordinary shares have the right to receive notices to attend and vote in general meetings of the Company’s shareholders, and the right to participated in dividends and other distributions upon liquidation. On September 27, 2022, the Company entered into an underwriting agreement with certain underwriters, pursuant to which the Company issued and sold, in an underwritten public offering, an aggregate of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share. b. Warrants to investors: As part of its 2017 investment round, the Company granted certain investors 4,323,978 warrants with an expiration date in July 2022. As of July 3, 2022, 1,010,466 of such warrants had been exercised into the Company’s ordinary shares and the remaining 3,313,512 warrants expired.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	NOTE 8:- SHARE-BASED COMPENSATION a. Option plans: On November 23, 2014, the Company’s Board of Directors approved, subject to the approval of the shareholders, creation of the Company’s ordinary C share class, with nominal value NIS 0.01 per share and classification of 1,500,000 ordinary shares for such class of shares, whereby 1,152,044 of such shares were allocated to the Company’s employees under the amended 2014 Israel Share Option Plan (the “2014 Plan”). The exercise price of the options granted under the 2014 Plan may not be less than the nominal value of the shares into which the options are exercised. The options vest primarily over three years. There are no cash settlement alternatives. On December 29, 2014, the Company’s shareholders ratified and approved the aforesaid actions. On January 23, 2017, the Company’s Board of Directors approved the Company’s 2017 Share Incentive Plan (the “2017 Plan” and together with the 2014 Plan, the “Option Plans”), and the subsequent grant of options to the Company’s employees, officers and directors. Pursuant to the 2017 Plan, the Company initially reserved for issuance 312,867 ordinary shares, nominal value NIS 0.01 each. On February 28, 2017, the Company’s shareholders approved the 2017 Plan. The 2017 Plan provides for the grant of awards, including options, restricted shares and restricted share units to the Company’s directors, employees, officers, consultants and advisors. On June 26, 2017 and on December 28, 2017, the Company’s Board of Directors approved the reservation of 463,384 and 559,764 additional ordinary shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of 1,338,015 ordinary Shares). On February 25, 2021 and November 17, 2021, the board of directors and shareholders, respectively, approved an amendment and restatement of the 2017 Plan. The 2017 Plan, as amended, also contains an “evergreen” provision, which provides for an automatic allotment of ordinary shares to be added every year to the pool of ordinary shares available for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each year (beginning January 1, 2022), the number of ordinary shares available under the 2017 Plan automatically increases by the lesser of the following: (i) 4% of our outstanding ordinary shares on the last day of the immediately preceding year; and (ii) an amount determined in advance of January 1 by the board of directors. The Company estimates the fair value of stock options granted using the binominal option-pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon the Company’s historical share price and historical volatilities of similar entities in the related sector index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The following table lists the inputs to the binomial option-pricing model used for the fair value measurement of equity-settled share options for the nine months ended September 30, 2022 and 2021: Nine months ended 2022 2021 (unaudited) Dividend yield 0% 0% Expected volatility of the share prices 66%-67% 66% Risk-free interest rate 1.8% - 3.5% 1.3% - 1.6% Expected term (in years) 8 8 Based on the above inputs, the fair value of the options was determined to be $0.99 - $1.85 per option at the grant date. b. The following table summarizes the number of options granted to employees under the Option Plans as of September 30, 2022 and related information: Number of Weighted (unaudited) (unaudited) Balance as of December 31, 2021 4,411,424 $ 6.01 Granted 2,233,150 2.60 Exercised (47,426 ) 1.60 Forfeited (378,379 ) 6.52 Expired (144,717 ) 5.22 Balance as of September 30, 2022 6,074,052 4.78 Exercisable as of September 30, 2022 2,696,432 $ 5.93 As of September 30, 2022, there are $10,964 of total unrecognized costs related to share-based compensation that are expected to be recognized over a period of up to four years. c. A summary of restricted shares and restricted shares unit activity as of September 30, 2022 is as follows: Number of Weighted (unaudited) (unaudited) Unvested as of December 31, 2021 531,477 $ 5.48 Granted 1,203,650 2.77 Vested (121,768 ) 6.04 Forfeited (124,670 ) 5.21 Unvested as of September 30, 2022 1,488,689 $ 3.27 d. The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine months ended September 30, 2022 and 2021 is comprised as follows: Three months ended September 30, Nine months ended 2022 2021 2022 2021 (unaudited) Research and development expenses, net $ 533 $ 368 $ 1,551 $ 1,051 Commercial expenses 328 253 976 653 General and administrative expenses 438 476 1,302 1,418 Total share-based compensation $ 1,299 $ 1,097 $ 3,829 $ 3,122

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Basic and Diluted Net Loss Per Share [Abstract]
BASIC AND DILUTED NET LOSS PER SHARE	NOTE 9:- BASIC AND DILUTED NET LOSS PER SHARE Basic net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares outstanding during each year. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period, in accordance with ASC No. 260-10 “Earnings Per Share”. The Company has a loss for the three and nine months ended September 30, 2022 and 2021; hence all potentially dilutive ordinary shares were excluded due to their anti-dilutive effect. Details of the number of shares and loss used in the computation of loss per share: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Weighted Net loss Weighted Net loss Weighted Net loss Weighted Net loss For the computation of basic and diluted loss 60,440,765 17,802 59,281,243 23,173 59,821,655 56,579 59,219,757 65,916 All outstanding convertible senior note options, warrants, outstanding share options, and restricted shares for the three and nine months ended September 30, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The total number of potential shares excluded from the calculation of diluted net loss per share are as follows: Three months ended Nine months ended 2022 2021 2022 2021 (unaudited) Convertible senior notes 4,222,973 4,222,973 4,222,973 3,495,941 Warrants 108,049 3,313,512 2,233,283 3,313,512 Outstanding share options 5,189,188 4,336,907 4,964,826 4,069,491 Restricted shares 1,140,318 202,404 1,008,551 138,850 Total 10,660,528 12,075,796 12,429,633 11,017,794

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates: The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.
Convertible senior notes	b. Convertible senior notes: The Company accounts for its convertible senior notes in accordance with ASC 470-20 “Debt with Conversion and Other Options.” The Company early adopted ASU 2020-06 using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.
Basic and diluted net loss per share	c. Basic and diluted net loss per share: The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis. These participating securities do not contractually require the holders of such shares to participate in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities. The Company’s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive ordinary shares are anti-dilutive.

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of operating lease costs	Nine months ended 2022 2021 (unaudited) (unaudited) Operating lease costs $ 2,093 $ 1,754 Short-term lease costs 92 84 Total lease costs $ 2,185 $ 1,838
Schedule of operating leases	Nine months (unaudited) Weighted average remaining lease term (in years) 3.88 Weighted average discount rate 2.61 %
Schedule of maturities of lease liabilities	As of 2022 $ 654 2023 1,589 2024 1,595 2025 1,195 2026 700 Thereafter 538 Total undiscounted lease payments 6,271 Less: Imputed interest (217 ) Present value of lease liabilities $ 6,054

Convertible Senior Notes, Net (

Convertible Senior Notes, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Convertible Senior Notes, Net [Abstract]
Schedule of liability measured at its amortized cost	As of Liability component: Principal amount $ 75,000 Issuance costs (4,223 ) Net of issuance costs 70,777 Amortized issuance costs 1,222 Net carrying amount $ 71,999

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements [Abstract]
Schedule of fair value	September 30, 2022 December 31, 2021 Level 1 Level 2 Total Level 1 Level 2 Total Financial assets: Money market funds included in cash and cash equivalents $ 49,395 $ - $ 49,935 $ 51,021 $ - $ 51,021 Marketable securities: Corporate debentures - 2,841 2,841 - 19,605 19,605 Government debentures - 3,383 3,383 - 20,429 20,429 Total assets measured at fair value $ 49,395 $ 6,224 $ 55,619 $ 51,021 $ 40,034 $ 91,055

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Compensation [Abstract]
Schedule of fair value measurement of equity-settled share options	Nine months ended 2022 2021 (unaudited) Dividend yield 0% 0% Expected volatility of the share prices 66%-67% 66% Risk-free interest rate 1.8% - 3.5% 1.3% - 1.6% Expected term (in years) 8 8
Schedule of number of options granted	Number of Weighted (unaudited) (unaudited) Balance as of December 31, 2021 4,411,424 $ 6.01 Granted 2,233,150 2.60 Exercised (47,426 ) 1.60 Forfeited (378,379 ) 6.52 Expired (144,717 ) 5.22 Balance as of September 30, 2022 6,074,052 4.78 Exercisable as of September 30, 2022 2,696,432 $ 5.93
Schedule of restricted shares and restricted shares	Number of Weighted (unaudited) (unaudited) Unvested as of December 31, 2021 531,477 $ 5.48 Granted 1,203,650 2.77 Vested (121,768 ) 6.04 Forfeited (124,670 ) 5.21 Unvested as of September 30, 2022 1,488,689 $ 3.27
Schedule of share-based compensation expense	Three months ended September 30, Nine months ended 2022 2021 2022 2021 (unaudited) Research and development expenses, net $ 533 $ 368 $ 1,551 $ 1,051 Commercial expenses 328 253 976 653 General and administrative expenses 438 476 1,302 1,418 Total share-based compensation $ 1,299 $ 1,097 $ 3,829 $ 3,122

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Basic and Diluted Net Loss Per Share [Abstract]
Schedule of number of shares and loss used in the computation of net loss per share	Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (unaudited) (unaudited) Weighted Net loss Weighted Net loss Weighted Net loss Weighted Net loss For the computation of basic and diluted loss 60,440,765 17,802 59,281,243 23,173 59,821,655 56,579 59,219,757 65,916
Schedule of outstanding convertible senior note options, warrants, outstanding share options, and restricted shares	Three months ended Nine months ended 2022 2021 2022 2021 (unaudited) Convertible senior notes 4,222,973 4,222,973 4,222,973 3,495,941 Warrants 108,049 3,313,512 2,233,283 3,313,512 Outstanding share options 5,189,188 4,336,907 4,964,826 4,069,491 Restricted shares 1,140,318 202,404 1,008,551 138,850 Total 10,660,528 12,075,796 12,429,633 11,017,794

General (Details)

General (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($)	Dec. 31, 2021
Accounting Policies [Abstract]
Response rate percentage, description	Among the 19 patients with NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate of 68%.
Clinical trial on outcomes description		The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at two years of 78% (95% CI, 51%-91%) and a safety profile similar to that reported previously.
Issuance costs	$ 18,100,000
Accumulated deficit	394,036
Cash	$ 54,246
Operating segment	1

Leases (Details)

Leases (Details)	Sep. 30, 2022
Leases [Abstract]
Lease term	6 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule of Operating Lease Costs [Abstract]
Operating lease costs	$ 2,093	$ 1,754
Short-term lease costs	92	84
Total lease costs	$ 2,185	$ 1,838

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of operating leases	Sep. 30, 2022
Schedule of Operating Leases [Abstract]
Weighted average remaining lease term (in years)	3 years 10 months 17 days
Weighted average discount rate	2.61%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of maturities of lease liabilities $ in Thousands	Sep. 30, 2022 USD ($)
Schedule of Maturities of Lease Liabilities [Abstract]
2022	$ 654
2023	1,589
2024	1,595
2025	1,195
2026	700
Thereafter	538
Total undiscounted lease payments	6,271
Less: Imputed interest	(217)
Present value of lease liabilities	$ 6,054

Convertible Senior Notes, Net_2

Convertible Senior Notes, Net (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Feb. 16, 2021	Sep. 30, 2022
Convertible Senior Notes, Net (Details) [Line Items]
Annual interest percentage	5.875%
Maturity date	Feb. 15, 2026
Convertible notes payable		$ 1,000
Ordinary shares (in Shares)		56.3063
Principal amount		$ 1,000
Exchange price (in Dollars per share)		$ 17.76
Repurchase price		100%
Exchange price percentage		130%
Convertible notes		$ 4,223
Effective interest rate		7.37%
Convertible Notes [Member]
Convertible Senior Notes, Net (Details) [Line Items]
Aggregate principal amount	$ 75,000
Principal amount		$ 1,000
Repurchase price		100%

Convertible Senior Notes, Net_3

Convertible Senior Notes, Net (Details) - Schedule of liability measured at its amortized cost $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Liability component:
Principal amount	$ 75,000
Issuance costs	(4,223)
Net of issuance costs	70,777
Amortized issuance costs	1,222
Net carrying amount	$ 71,999

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of fair value - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Financial assets:
Money market funds included in cash and cash equivalents	$ 49,935	$ 51,021
Marketable securities:
Corporate debentures	2,841	19,605
Government debentures	3,383	20,429
Total assets measured at fair value	55,619	91,055
Level 1 [Member]
Financial assets:
Money market funds included in cash and cash equivalents	49,395	51,021
Marketable securities:
Corporate debentures
Government debentures
Total assets measured at fair value	49,395	51,021
Level 2 [Member]
Financial assets:
Money market funds included in cash and cash equivalents
Marketable securities:
Corporate debentures	2,841	19,605
Government debentures	3,383	20,429
Total assets measured at fair value	$ 6,224	$ 40,034

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Contingent Liabilities and Commitments (Details) [Line Items]
Bank guarantees amount	$ 2,929
Investment center grant amount	2,786
Aggregate amount	36,800
Royalty-bearing grants	34,200
Non-royalty-bearing grants	$ 2,600
Percentage of interest rate	100%
Total grants	$ 42,200
Minimum [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Royalties rate	3%
Maximum [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Royalties rate	3.50%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - $ / shares		9 Months Ended
	Jul. 03, 2022	Sep. 30, 2022	Sep. 27, 2022
Shareholders' Equity (Details) [Line Items]
Underwriters description		Subject to the Company’s amended and restated Articles of Association, the holders of the Company’s ordinary shares have the right to receive notices to attend and vote in general meetings of the Company’s shareholders, and the right to participated in dividends and other distributions upon liquidation.
Ordinary shares			12,905,000
Price per share (in Dollars per share)			$ 1.55
Expire date		July 2022
Remaining shares	3,313,512
2017 Investor [Member]
Shareholders' Equity (Details) [Line Items]
Granted Warrants		4,323,978
Warrant [Member]
Shareholders' Equity (Details) [Line Items]
Granted Warrants	1,010,466

Share-Based Compensation (Detai

Share-Based Compensation (Details) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Nov. 23, 2014 ₪ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 28, 2017 shares	Jun. 26, 2017 shares	Jan. 23, 2017 ₪ / shares shares
Share-Based Compensation (Details) [Line Items]
Options vest period	3 years	4 years
Ordinary shares outstanding percentage		4%
Share-based compensation non-vested (in Dollars) | $		$ 10,964
2017 Share Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Nominal per share value (in New Shekels per share) | ₪ / shares					₪ 0.01
Number of shares reserved for issuance		1,338,015	559,764	463,384	312,867
Minimum [Member]
Share-Based Compensation (Details) [Line Items]
Grant date fair value per share (in Dollars per share) | $ / shares		$ 0.99
Maximum [Member]
Share-Based Compensation (Details) [Line Items]
Grant date fair value per share (in Dollars per share) | $ / shares		$ 1.85
Ordinary C Share [Member]
Share-Based Compensation (Details) [Line Items]
Nominal per share value (in New Shekels per share) | ₪ / shares	₪ 0.01
Ordinary shares	1,500,000
Ordinary C Share [Member] | 2014 Israel Share Option Plan [Member]
Share-Based Compensation (Details) [Line Items]
Ordinary shares issued	1,152,044

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options [Line Items]
Dividend yield	0%	0%
Expected volatility of the share prices		66%
Expected term (in years)	8 years	8 years
Minimum [Member]
Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options [Line Items]
Expected volatility of the share prices	66%
Risk-free interest rate	1.80%	1.30%
Maximum [Member]
Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options [Line Items]
Expected volatility of the share prices	67%
Risk-free interest rate	3.50%	1.60%

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of number of options granted	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Schedule Of Number Of Options Granted Abstract
Number of options, beginning balance | shares	4,411,424
Weighted average exercise price, beginning balance | $ / shares	$ 6.01
Number of options, Granted | shares	2,233,150
Weighted average exercise price, Granted | $ / shares	$ 2.6
Number of options, Exercised | shares	(47,426)
Weighted average exercise price, Exercised | $ / shares	$ 1.6
Number of options, Forfeited | shares	(378,379)
Weighted average exercise price, Forfeited | $ / shares	$ 6.52
Number of options, Expired | shares	(144,717)
Weighted average exercise price, Expired | $ / shares	$ 5.22
Number of options, ending balance | shares	6,074,052
Weighted average exercise price, ending balance | $ / shares	$ 4.78
Number of options, Exercisable | shares	2,696,432
Weighted average exercise price, Exercisable | $ / shares	$ 5.93

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of restricted shares and restricted shares	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Schedule Of Restricted Shares And Restricted Shares Abstract
Number of restricted shares and restricted share units, Unvested beginning | shares	531,477
Weighted average grant date fair value, Unvested beginning | $ / shares	$ 5.48
Number of restricted shares and restricted share units, Granted | shares	1,203,650
Weighted average grant date fair value, Granted | $ / shares	$ 2.77
Number of restricted shares and restricted share units, Vested | shares	(121,768)
Weighted average grant date fair value, Vested | $ / shares	$ 6.04
Number of restricted shares and restricted share units, Forfeited | shares	(124,670)
Weighted average grant date fair value, Forfeited | $ / shares	$ 5.21
Number of restricted shares and restricted share units, Unvested ending | shares	1,488,689
Weighted average grant date fair value, Unvested ending | $ / shares	$ 3.27

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule Of Share Based Compensation Expense Abstract
Research and development expenses, net	$ 533	$ 368	$ 1,551	$ 1,051
Commercial expenses	328	253	976	653
General and administrative expenses	438	476	1,302	1,418
Total share-based compensation	$ 1,299	$ 1,097	$ 3,829	$ 3,122

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule of Number of Shares and Loss Used in the Computation of Net Loss Per Share [Abstract]
Weighted number of shares	60,440,765	59,281,243	59,821,655	59,219,757
Net loss attributable to Ordinary shares of the Company	$ 17,802	$ 23,173	$ 56,579	$ 65,916

Basic and Diluted Net Loss Pe_4

Basic and Diluted Net Loss Per Share (Details) - Schedule of outstanding convertible senior note options, warrants, outstanding share options, and restricted shares - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule of Outstanding Convertible Senior Note Options Warrants Outstanding Share Options and Restricted Shares [Abstract]
Convertible senior notes	4,222,973	4,222,973	4,222,973	3,495,941
Warrants	108,049	3,313,512	2,233,283	3,313,512
Outstanding share options	5,189,188	4,336,907	4,964,826	4,069,491
Restricted shares	1,140,318	202,404	1,008,551	138,850
Total	10,660,528	12,075,796	12,429,633	11,017,794